Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantitative Longitudinal Observation of Neurodegeneration in Patients With Moderate to Advanced Primary Parkinson's Disease Using ¹⁸F-DOPA PET-CT Molecular Imaging and Blood Biomarkers

NCT07919262 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07919262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Quantitative Longitudinal Observation of Neurodegeneration in Patients With Moderate to Advanced Primary Parkinson's Disease Using ¹⁸F-DOPA PET-CT Molecular Imaging and Blood Biomarkers
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Observational
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
April 30, 2028
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson disease

Arms

As registered; 1 arm.

  • Idiopathic Parkinson's Disease Cohort Brain PET Examination, Clinical assessment, blood sampling and brain PET examination

    Patients with moderate to advanced idiopathic Parkinson's disease who will undergo clinical assessments, blood sample collection, and brain PET examinations, with longitudinal follow-up for 1 year.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change in Putamen 18F-DOPA PET Specific Binding Ratio (SBR) from Baseline to 12 Months Baseline and 12 months after enrollment

    Change in 18F-DOPA PET specific binding ratio (SBR) in the putamen from baseline to 12 months after enrollment. SBR is calculated as the ratio of radiotracer uptake in the putamen to that in a reference region. Higher SBR values indicate greater presynaptic dopaminergic function.

Lead sponsor's other trials

Xuanwu Hospital, Beijing, most recent start first.

Similar trials

Same condition (Parkinson Disease) and phase, most recent start first.